- Home
- JILL vs DRUG Comparison
JILL vs DRUG Comparison
Compare JILL & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JILL
- DRUG
- Stock Information
- Founded
- JILL 1959
- DRUG 2019
- Country
- JILL United States
- DRUG United States
- Employees
- JILL N/A
- DRUG N/A
- Industry
- JILL Clothing/Shoe/Accessory Stores
- DRUG Pharmaceuticals and Biotechnology
- Sector
- JILL Consumer Discretionary
- DRUG Health Care
- Exchange
- JILL Nasdaq
- DRUG Nasdaq
- Market Cap
- JILL 233.1M
- DRUG 199.7M
- IPO Year
- JILL 2017
- DRUG N/A
- Fundamental
- Price
- JILL $16.47
- DRUG $35.46
- Analyst Decision
- JILL Buy
- DRUG Strong Buy
- Analyst Count
- JILL 3
- DRUG 7
- Target Price
- JILL $25.00
- DRUG $83.25
- AVG Volume (30 Days)
- JILL 100.2K
- DRUG 67.0K
- Earning Date
- JILL 09-03-2025
- DRUG 08-13-2025
- Dividend Yield
- JILL 1.94%
- DRUG N/A
- EPS Growth
- JILL N/A
- DRUG N/A
- EPS
- JILL 2.24
- DRUG N/A
- Revenue
- JILL $602,968,000.00
- DRUG N/A
- Revenue This Year
- JILL $1.16
- DRUG N/A
- Revenue Next Year
- JILL $1.46
- DRUG N/A
- P/E Ratio
- JILL $7.35
- DRUG N/A
- Revenue Growth
- JILL N/A
- DRUG N/A
- 52 Week Low
- JILL $13.36
- DRUG $0.94
- 52 Week High
- JILL $38.97
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- JILL 60.89
- DRUG 74.46
- Support Level
- JILL $14.52
- DRUG $25.56
- Resistance Level
- JILL $16.87
- DRUG $26.83
- Average True Range (ATR)
- JILL 0.54
- DRUG 1.83
- MACD
- JILL 0.18
- DRUG 1.03
- Stochastic Oscillator
- JILL 83.16
- DRUG 84.29
About JILL J. Jill Inc.
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). Revenue is derived from the sale of apparel and accessory merchandise through the company's Retail and Direct channels, which include website and catalog phone orders. Revenue also includes shipping and handling fees collected from customers.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.